Dr. Olga Zaytseva is researching the genetic changes that drive some low-grade gliomas. Here, Olga explains what drew her to brain cancer research, why she focuses on low-grade glioma and what vorasidenib could mean for people living with these tumours.
What drew you to brain cancer research?
During my PhD, I studied a gene controlling growth in ovarian flies. When that same gene appeared mutated in brain cancer, it challenged everything we expected. I needed to understand why – and that curiosity brought me where I am today.
Why focus on low-grade glioma?
Although they’re classed as ‘low-grade’, these cancers (namely astrocytoma and oligodendroglioma) are devastating. People are often diagnosed in their 30s or 40s, while building careers and raising families. They may live for years with seizures, cognitive decline and changes in behaviour.
What does your research involve?
We study patient tumour samples to identify the genetic changes making cells cancerous. Once we understand what has gone wrong, we can test which drugs may target those changes.
What does vorasidenib mean for patients?
Vorasidenib targets the IDH mutation driving some low-grade gliomas. It can slow tumour progression and give eligible patients more time before their cancer worsens – and more time living well with the people they love.
Find out more about how vorasidenib targets brain cancer cells in the video below:
Olga’s research is helping bring better treatment within reach for patients too often overlooked. That progress takes time, persistence and people who believe every single patient deserves hope.
Your Support Makes Research Possible
Thanks to you, researchers like Olga can continue investigating brain cancer and working towards better treatment options for people affected by the disease.
